Abstract
Meeting the Challenges in Pain Therapeutics Development
Neurotherapeutics, Vol.22(4), e00668
07/2025
DOI: 10.1016/j.neurot.2025.e00668
Abstract
With the exception of migraine therapeutics, there have been no novel drugs approved for pain in the last five years. One reason for this is the continued reduction in clinical success rates for pain drugs relative to novel drugs for other indications. Reasons most cited for these clinical failures include the following: poor predictive validity of preclinical pain models, significant heterogeneity in pain patient populations, lack of target engagement or patient selection biomarkers, large placebo effects in clinical trials and therapeutic index challenges. This ASENT symposium attempts to address these issues by highlighting emerging new therapeutics, innovative clinical trial design and new multi-modal approaches to pain biomarker development. These concepts will be discussed through three presentations and an interactive panel discussion focused on the pain therapeutic landscape of the future. Speakers include: Dr. James Sahn, 4E Therapeutics, Dr. Emine Bayman, University of Iowa and Dr. Daniel Rotroff, Cleveland Clinic.
Details
- Title: Subtitle
- Meeting the Challenges in Pain Therapeutics Development
- Creators
- Mary A. Pelleymounter - National Institute of Neurological Disorders and StrokeDonna Hammond - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Neurotherapeutics, Vol.22(4), e00668
- DOI
- 10.1016/j.neurot.2025.e00668
- ISSN
- 1878-7479
- eISSN
- 1878-7479
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 07/2025
- Academic Unit
- Iowa Neuroscience Institute; Anesthesia
- Record Identifier
- 9984948120702771
Metrics
1 Record Views